Bibliography
- Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2:346-57
- Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298-304
- Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011;23:346-51
- Antoni C, Krueger GG, de Vlam K, et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
- Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
- Gladman DD, Sampalis JS, Illouz O, et al. ACCLAIM Study Investigators. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898-906
- Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010;69:394-9
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; doi: 10.1016/S0140-6736(13)60594-2
- Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48
- Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210-12
- Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl 2012;89:4-6
- Adisen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin Exp Dermatol 2008;33:164-6
- Cuchacovich R, Garcia-Valladares I, Espinoza LR. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol 2012;39:187-93
- Sanduzzi A, Bocchino M, Atteno M, et al. Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 2012;89:82-5
- Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future directions. Expert Opin Pharmacother 2013;14:1755-64